{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:52Z","timestamp":1793502712120,"version":"4.5.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Antimicrobial resistance (AMR) in Gram-negative bacteria (GNB) poses a significant global health concern, contributing to increased infections, mortality rates, and healthcare costs. This review discusses the main clinical manifestations, therapeutic options, and recent findings in managing antibiotic-resistant GNB, with a focus on difficult-to-treat infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Difficult-to-treat resistance (DTR) is a novel classification that identifies GNB exhibiting intermediate or resistant phenotypes to first-line agents in the carbapenem, beta-lactam, and fluoroquinolone categories. The main pathogens implicated in severe infections include DTR Enterobacterales, DTR\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      , and DTR\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii.<\/jats:italic>\n                      Although the clinical implications of DTR strains are still under investigation, certain studies have linked them to prolonged hospital stays and poor patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Severe infections caused by DTR-GNB pose a formidable challenge for healthcare providers and represent a growing global health issue. The proper administration and optimization of novel antibiotics at our disposal are of paramount importance for combating bacterial resistance and improving patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001074","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:17:41Z","timestamp":1693279061000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Severe infections caused by difficult-to-treat Gram-negative bacteria"],"prefix":"10.1097","volume":"29","author":[{"given":"Silvia","family":"Dettori","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Portunato","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience"},{"name":"Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing epidemiology and decreased mortality associated with carbapenem-resistant Gram-negative bacteria, 2000\u20132017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/CCM.0000000000001013","article-title":"Impact of sepsis classification and multidrug-resistance status on outcome among patients treated with appropriate therapy","volume":"43","author":"Burnham","year":"2015","journal-title":"Crit Care Med"},{"key":"R7-20250729","first-page":"405","article-title":"Bloodstream infections in ICU with increased resistance: epidemiology and outcomes","volume":"81","author":"Dimopoulos","year":"2015","journal-title":"Minerva Anestesiol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajic.2017.09.005","article-title":"The epidemiology of nonventilator hospital-acquired pneumonia in the United States","volume":"46","author":"Giuliano","year":"2018","journal-title":"Am J Infect Control"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CCM.0000000000003553","article-title":"A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia","volume":"47","author":"Ibn Saied","year":"2019","journal-title":"Crit Care Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"219","author":"Talbot","year":"2019","journal-title":"J Infect Dis"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1038\/s41598-021-95852-4","article-title":"Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia","volume":"11","author":"Lakbar","year":"2021","journal-title":"Sci Rep"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CMR.00002-14","article-title":"Population-based epidemiology and microbiology of community-onset bloodstream infections","volume":"27","author":"Laupland","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/s12879-021-06496-8","article-title":"Nonfermentative Gram-negative bloodstream infection in northern Italy: a multicenter cohort study","volume":"21","author":"Pascale","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciaa084","article-title":"Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data","volume":"71","author":"Huh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00134-019-05841-5","article-title":"Postoperative abdominal infections: epidemiology, operational definitions, and outcomes","volume":"46","author":"Bassetti","year":"2020","journal-title":"Intensive Care Med"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00134-019-05819-3","article-title":"Epidemiology of intra-abdominal infection and sepsis in critically ill patients: \u2018AbSeS\u2019, a multinational observational cohort study and ESICM Trials Group Project","volume":"45","author":"Blot","year":"2019","journal-title":"Intensive Care Med"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13054-015-0789-9","article-title":"Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis","volume":"19","author":"Montravers","year":"2015","journal-title":"Crit Care"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jhin.2021.09.021","article-title":"Risk factors and mortality associated with multidrug-resistant Gram-negative bacterial infection in adult patients following abdominal surgery","volume":"119","author":"Lin","year":"2022","journal-title":"J Hosp Infect"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10096-011-1347-2","article-title":"Multidrug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study","volume":"31","author":"Alexiou","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"177","DOI":"10.11604\/pamj.2014.19.177.4307","article-title":"Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt","volume":"19","author":"Hasanin","year":"2014","journal-title":"Pan Afr Med J"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/1471-2334-14-420","article-title":"Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome","volume":"14","author":"De Waele","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcrc.2019.02.029","article-title":"MARS consortium: epidemiology and outcomes of source control procedures in critically ill patients with intra-abdominal infection","volume":"52","author":"van de Groep","year":"2019","journal-title":"J Crit Care"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"106591","DOI":"10.1016\/j.ijantimicag.2022.106591","article-title":"Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study","volume":"60","author":"Arvaniti","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ccc.2013.03.014","article-title":"Urinary tract infection","volume":"29","author":"Nicolle","year":"2013","journal-title":"Crit Care Clin"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/ijccm.IJCCM_434_17","article-title":"Diagnosing catheter-associated urinary tract infection in critically ill patients: do the guidelines help?","volume":"22","author":"Saran","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13756-019-0656-6","article-title":"Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study","volume":"8","author":"Gomila","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"106184","DOI":"10.1016\/j.ijantimicag.2020.106184","article-title":"Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections","volume":"56","author":"Bassetti","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.3390\/biomedicines10123268","article-title":"Ten years of KPC-Kp bloodstream infections experience: impact of early appropriate empirical therapy on mortality","volume":"10","author":"Corcione","year":"2022","journal-title":"Biomedicines"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiinfective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u2018Old\u2019 and the \u2018New\u2019 antibiotics for MDR gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14740338.2022.1990262","article-title":"Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections","volume":"21","author":"Bassetti","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","article-title":"Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections","volume":"15","author":"Bassetti","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-20250729","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","article-title":"An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam","volume":"9","author":"Wenzler","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"ofab141","DOI":"10.1093\/ofid\/ofab141","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant st-512 klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3","volume":"8","author":"Tiseo","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R55-20250729","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1099\/jmm.0.001142","article-title":"In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015\u20132017","volume":"69","author":"Lob","year":"2020","journal-title":"J Med Microbiol"},{"key":"R56-20250729","doi-asserted-by":"crossref","first-page":"e0292722","DOI":"10.1128\/spectrum.02927-22","article-title":"Imipenem-relebactam susceptibility in Enterobacterales isolates recovered from ICU patients from Spain and Portugal (SUPERIOR and STEP Studies)","volume":"10","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R57-20250729","doi-asserted-by":"crossref","first-page":"115568","DOI":"10.1016\/j.diagmicrobio.2021.115568","article-title":"Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales","volume":"102","author":"Bail","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R58-20250729","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R59-20250729","doi-asserted-by":"crossref","first-page":"ofab554","DOI":"10.1093\/ofid\/ofab554","article-title":"Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections","volume":"8","author":"Rebold","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R60-20250729","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R61-20250729","doi-asserted-by":"crossref","first-page":"e0201121","DOI":"10.1128\/aac.02011-21","article-title":"New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae","volume":"66","author":"Nurjadi","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R62-20250729","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/ciac082","article-title":"Cefiderocol for the treatment of metallo-\u03b2-lactamases producing gram-negative bacilli: lights and shadows from the literature","volume":"75","author":"Falcone","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R63-20250729","doi-asserted-by":"crossref","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-nonsusceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"R64-20250729","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R65-20250729","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R66-20250729","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10096-021-04197-3","article-title":"Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"40","author":"Maraki","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R67-20250729","doi-asserted-by":"crossref","first-page":"115674","DOI":"10.1016\/j.diagmicrobio.2022.115674","article-title":"Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-\u03b2-lactamase-producing Enterobacterales","volume":"103","author":"Biagi","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R68-20250729","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"R69-20250729","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R70-20250729","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"R71-20250729","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138161213804070311","article-title":"Mechanisms of \u03b2-lactam resistance among Pseudomonas aeruginosa","volume":"19","author":"Wolter","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R72-20250729","doi-asserted-by":"crossref","first-page":"614058","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile carbapenemase genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon","year":"2021","journal-title":"Front Microbiol"},{"key":"R73-20250729","doi-asserted-by":"crossref","first-page":"249856","DOI":"10.1155\/2014\/249856","article-title":"Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria","volume":"2014","author":"Dortet","year":"2014","journal-title":"Biomed Res Int"},{"key":"R74-20250729","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, noninferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R75-20250729","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R76-20250729","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection"},{"key":"R77-20250729","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R78-20250729","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"R79-20250729","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R80-20250729","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R81-20250729","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R82-20250729","doi-asserted-by":"crossref","first-page":"106270","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R83-20250729","doi-asserted-by":"crossref","first-page":"e0229221","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH Study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R84-20250729","doi-asserted-by":"crossref","first-page":"e02165","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R85-20250729","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R86-20250729","doi-asserted-by":"crossref","first-page":"e01008-17","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R87-20250729","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R88-20250729","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"R89-20250729","doi-asserted-by":"crossref","first-page":"1048633","DOI":"10.3389\/fcimb.2022.1048633","article-title":"Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: a real-life study","volume":"12","author":"Larcher","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R90-20250729","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10096-020-04053-w","article-title":"Is it time to move away from polymyxins?: evidence and alternatives","volume":"40","author":"Soman","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R91-20250729","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/antibiotics11121739","article-title":"Pharmacokinetic\/pharmacodynamic analysis of continuous-infusion fosfomycin in combination with extended-infusion cefiderocol or continuous-infusion ceftazidime-avibactam in a case series of difficult-to-treat resistant pseudomonas aeruginosa bloodstream infections and\/or hospital-acquired pneumonia","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R92-20250729","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1574-6968.2006.00195.x","article-title":"The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii","volume":"258","author":"Turton","year":"2006","journal-title":"FEMS Microbiol Lett"},{"key":"R93-20250729","doi-asserted-by":"crossref","first-page":"e20200248","DOI":"10.1590\/0037-8682-0248-2020","article-title":"Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings","volume":"53","author":"Kurihara","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"R94-20250729","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"R95-20250729","doi-asserted-by":"crossref","first-page":"305784","DOI":"10.1155\/2014\/305784","article-title":"Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries","volume":"2014","author":"Djahmi","year":"2014","journal-title":"Biomed Res Int"},{"key":"R96-20250729","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12879-020-05026-2","article-title":"Clinical efficacy and safety of polymyxins based versus nonpolymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis","volume":"20","author":"Lyu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R97-20250729","first-page":"11","article-title":"Triple combination therapy with high-dose ampicillin\/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study","volume":"27","author":"Assimakopoulos","year":"2019","journal-title":"Infez Med"},{"key":"R98-20250729","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"R99-20250729","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"R100-20250729","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol - compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R101-20250729","doi-asserted-by":"crossref","first-page":"e0047922","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R102-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R103-20250729","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CCM.0000000000002011","article-title":"Impact of source control in patients with severe sepsis and septic shock","volume":"45","author":"Mart\u00ednez","year":"2017","journal-title":"Crit Care Med"},{"key":"R104-20250729","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s00134-017-4782-4","article-title":"Effect of a multifaceted educational intervention for antiinfectious measures on sepsis mortality: a cluster randomized trial","volume":"43","author":"Bloos","year":"2017","journal-title":"Intensive Care Med"},{"key":"R105-20250729","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.1186\/cc13854","article-title":"Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock","volume":"18","author":"Azuhata","year":"2014","journal-title":"Crit Care"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:08:58Z","timestamp":1753819738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001074","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}